Physician profile
Carissa K Mowery
NPI 1518673045
$5,411.30
in general payments reported to CMS, 2019-2025
26 companies · $798 in 2025
The $798 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,292 · 2024: $3,321 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,411.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,827.89 | 2023-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $1,222.76 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $642.05 | 2023-2025 | Dificid, Zerbaxa, Prevymis |
| Abbvie INC. | $496.91 | 2023-2025 | |
| Axsome Therapeutics, INC. | $152.23 | 2023-2025 | Auvelity |
| Shionogi INC | $136.44 | 2024-2025 | Fetroja |
| Janssen Biotech, INC. | $127.73 | 2023 | Symtuza |
| Lilly USA, LLC | $107.42 | 2024 | Zepbound, Mounjaro |
| Vanda Pharmaceuticals INC. | $91.41 | 2024 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $71.26 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $68.29 | 2024 | Airsupra |
| Bavarian Nordic A/S | $66.23 | 2025 | |
| Sanofi-Aventis U.S. LLC | $57.72 | 2024-2025 | |
| Daiichi Sankyo INC. | $50.59 | 2024 | Injectafer |
| Paratek Pharmaceuticals, INC. | $35.74 | 2023-2024 | Nuzyra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $31.00 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $28.59 | 2024 | Rexulti |
| Philips North America LLC | $27.99 | 2024 | (Ck7) Extended Holter |
| Pfizer INC. | $26.48 | 2024 | |
| Melinta Therapeutics, LLC | $24.82 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
| Hologic Sales and Service, LLC | $24.69 | 2025 | Aptima |
| Janssen Pharmaceuticals, INC | $24.14 | 2024 | Spravato |
| Napo Pharmaceuticals INC | $23.95 | 2025 | Mytesi |
| Corium, LLC | $15.54 | 2023 | Azstarys |
| Shield Therapeutics INC | $15.46 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.97 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carissa Mowery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.